How Anti-Obesity Drugs are Redefining Pharma and Wellness with David Ricks and Fatima Cody Stanford

Two of the leading experts on anti-obesity drugs say the drugs are heralding a new era in medicine and could soon be used to treat a raft of other conditions. David Ricks, the chair and chief executive of Eli Lilly, and Dr. Fatima Cody Stanford, obesity medicine physician at Massachusetts General Hospital/Harvard Medical School, talk through the groundbreaking role of GLP-1 medications in transforming the treatment of obesity, and how the drug could potentially be used to treat alcohol use disorder or other addictions.